Werner Koopman, theme Mitochondrial diseases, received 400,000 euro as a member of the PD-MitoQUANT consortium. The latter is an EU-funded Innovative Medicines Initiative research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future.The project will run for three years, receiving 4.5 million euro in funding from the EU’s Horizon 2020 programme and 2.46 million euro in-kind from European Federation of Pharmaceutical Industries and Associations (EFPIA) members and Parkinson’s UK.
PD-MitoQUANT focuses on how mitochondria, the ‘powerhouses’ of the cell, contribute to cell death and neurodegeneration when they malfunction. The project involves 14 partners from 9 countries, including academic experts from the Royal College of Surgeons in Ireland, Institut du Cerveau et de la Moelle Epinière, German Center for Neurodegenerative Diseases, Neuroscience Institute of the National Research Council, University College London, Radboud University Medical Centre, the Centre National de la Recherche Scientifique, SMEs (GeneXplain GmbH, Mimetas, Pintail Limited), pharmaceutical companies (Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; UCB S.A.), and a patient advocacy organization (Parkinson’s UK).
Innovative Medicines Initiative (IMI): link.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more